Prepped June 10th- sorry for late post- Didnt realise it didnt publish.
Bears rip Amarin management to pieces saying this is doomed to failure and will never work. It is the first time this has ever been attempted.
I am not going into detail on this because I will link lots of items for your reading at leisure. (it should be part of your DD anyway).
Tom Lynch did a great job getting things together back when cash was scarce and kept Amarin ticking through its process. That was before FDA approval in July 2012.
Joe Zakrzewski Stepped up to take the lead and deep thinkers realised it was a good thing. Joe was in charge of a small company back in 2007 when it was purchased by GSK.
Who cares?
That small company was Reliant Pharmaceuticals. Reliant was a three trick pony and one trick was a trig lowering pill called Omacor. It was a complicated blend of various bits and bobs of chemicals with about 50% EPA.
Reliant got FDA approval in Nov 2004 and decided to go to market soon after. In July 2007 the drug started shipping to market and as sales began to increase and the market was educated it was scooped up by GSK in Nov 2007. Closed in Nov 2007.
5 years later the patent drops allowing access for generic copy cat versions into the market. Demand is dropping for Lovaza.
As you can see the model used by Amarin seems to be give a decent result..... Could we possibly get 1.65 billion for Amarin?
With 140,000,000 shares that would price us at $13 a share.. Not great. :( Let us hope the company goes for a little more than that.
Disclosure: I am long AMRN.
Additional disclosure: My disclosure is based on my opinion only and relevant information taken from conference call and various other sources of information. It has no importance in you making a decision to invest your money in AMRN or not.